These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26544651)

  • 1. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis.
    Mohammed K; Abu Dabrh AM; Benkhadra K; Al Nofal A; Carranza Leon BG; Prokop LJ; Montori VM; Faubion SS; Murad MH
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4012-20. PubMed ID: 26544651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal hormone therapy and the risk of stroke and venous thrombosis.
    Speroff L
    Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
    Rovinski D; Ramos RB; Fighera TM; Casanova GK; Spritzer PM
    Thromb Res; 2018 Aug; 168():83-95. PubMed ID: 29936403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.
    Oliver-Williams C; Glisic M; Shahzad S; Brown E; Pellegrino Baena C; Chadni M; Chowdhury R; Franco OH; Muka T
    Hum Reprod Update; 2019 Mar; 25(2):257-271. PubMed ID: 30508190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.
    Simon JA; Laliberté F; Duh MS; Pilon D; Kahler KH; Nyirady J; Davis PJ; Lefebvre P
    Menopause; 2016 Jun; 23(6):600-10. PubMed ID: 26953655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to the Letter: "Transdermal vs oral estrogen therapy and venous thromboembolism: upgrade the level of evidence" by Scarabin MC, et al.
    Mohammed K; Murad MH
    J Clin Endocrinol Metab; 2016 Feb; 101(2):L32. PubMed ID: 26840116
    [No Abstract]   [Full Text] [Related]  

  • 7. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.
    Laliberté F; Dea K; Duh MS; Kahler KH; Rolli M; Lefebvre P
    Menopause; 2018 Nov; 25(11):1297-1305. PubMed ID: 30358726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis.
    Scarabin PY
    Climacteric; 2018 Aug; 21(4):341-345. PubMed ID: 29570359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter to the Editor: "Transdermal vs Oral Estrogen Therapy and Venous Thromboembolism: Upgrade the Level of Evidence" by.
    Scarabin PY; Canonico M; Scarabin-Carré V; Oger E
    J Clin Endocrinol Metab; 2016 Feb; 101(2):L30-1. PubMed ID: 26840115
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.
    Bergendal A; Kieler H; Sundström A; Hirschberg AL; Kocoska-Maras L
    Menopause; 2016 Jun; 23(6):593-9. PubMed ID: 27023862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism.
    Renoux C; Dell'Aniello S; Brenner B; Suissa S
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):554-560. PubMed ID: 28326633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.
    Scarabin PY; Oger E; Plu-Bureau G;
    Lancet; 2003 Aug; 362(9382):428-32. PubMed ID: 12927428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
    Straczek C; Oger E; Yon de Jonage-Canonico MB; Plu-Bureau G; Conard J; Meyer G; Alhenc-Gelas M; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
    Circulation; 2005 Nov; 112(22):3495-500. PubMed ID: 16301339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.
    Bouligand J; Cabaret O; Canonico M; Verstuyft C; Dubert L; Becquemont L; Guiochon-Mantel A; Scarabin PY;
    Clin Pharmacol Ther; 2011 Jan; 89(1):60-4. PubMed ID: 21107315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study.
    Canonico M; Oger E; Conard J; Meyer G; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
    J Thromb Haemost; 2006 Jun; 4(6):1259-65. PubMed ID: 16706969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The benefits and risks of menopause hormone therapy for the cardiovascular system in postmenopausal women: a systematic review and meta-analysis.
    Gu Y; Han F; Xue M; Wang M; Huang Y
    BMC Womens Health; 2024 Jan; 24(1):60. PubMed ID: 38263123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women.
    Olié V; Canonico M; Scarabin PY
    Curr Opin Hematol; 2010 Sep; 17(5):457-63. PubMed ID: 20601871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMAS position statement: Managing menopausal women with a personal or family history of VTE.
    Tremollieres F; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Vujovic S; Rozenberg S; Rees M;
    Maturitas; 2011 Jun; 69(2):195-8. PubMed ID: 21489728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study.
    Renoux C; Dell'Aniello S; Suissa S
    J Thromb Haemost; 2010 May; 8(5):979-86. PubMed ID: 20230416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.